contraceptives, postcoital profile

Contraceptives, Postcoital: Contraceptive substances to be used after COITUS. These agents include high doses of estrogenic drugs; progesterone-receptor blockers; ANTIMETABOLITES; ALKALOIDS, and PROSTAGLANDINS. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	73346591
CHEMBL ID	2447915
MeSH ID	M0005121

Synonym
contraceptives, postcoital
postcoital contraceptives
CHEMBL2447915
O029200000

Excerpt	Reference	Relevance
" Some of these concerns include potentially increased risks of cardiovascular events (including arterial and venous disease), worries about possible effects on future fertility, feared teratogenic consequences following method failure or inadvertent use during pregnancy, exaggerated or extreme fears of adverse tolerability, and concerns about drug interactions with other medications."	( How safe is emergency contraception? Ellertson, C; Norris Turner, A, 2002)	0.31
" DES is considered safe only as an emergency contraceptive measure."	( FDA considers DES safe as 'morning-after' pill. , 1973)	0.25
"During a 1996 hearing, the US Food and Drug Administration (FDA) Reproductive Health Drugs Advisory Committee reached the unanimous conclusion that certain oral contraceptives (OCs) are safe and effective for use in an emergency postcoital regimen."	( FDA finds emergency postcoital contraception safe and effective. , 1996)	0.29
" A specialist conference in January this year concluded that the technique is safe and effective and would be particularly valuable in resource-poor countries."	( Cutting unsafe abortions. , 1998)	0.3
"Ulipristal acetate (UPA), a selective progesterone receptor modulator, when taken as a single 30-mg dose, is safe and effective for emergency contraception up to 5 days (120 h) following unprotected intercourse."	( Ulipristal acetate: a new emergency contraceptive that is safe and more effective than levonorgestrel. Fine, PM, 2011)	0.37
" The most commonly (>10%) reported adverse events included headache, nausea, and abdominal pain."	( Ulipristal acetate: review of the efficacy and safety of a newly approved agent for emergency contraception. Maltz, FN; Richardson, AR, 2012)	0.38
" We revised the literature to concern most of the data available on the role of EC and moreover clarifying the available methods, the action windows of the accessible devices, the adverse events and the controindications."	( Nowadays which emergency contraception? Comparison between past and present: latest news in terms of clinical efficacy, side effects and contraindications. D'Antona, D; Di Gangi, S; Fanelli, T; Gizzo, S; Nardelli, GB; Omar, A; Patrelli, TS; Saccardi, C; Zambon, A, 2012)	0.38
" The main side effect was frequent menstrual irregularities."	( A systematic review of effectiveness and safety of different regimens of levonorgestrel oral tablets for emergency contraception. Al-Amin, MM; Rahman, MM; Reza, HM; Shohel, M; Uddin, MM; Zaman, A, 2014)	0.4
"This review will evaluate all the information about the potential adverse effects and tolerability of each method of EC by putting them in balance with their safety and effectiveness."	( Consequences of emergency contraceptives: the adverse effects. Chabbert-Buffet, N; Daraï, E; Keller, V; Thomin, A, 2014)	0.4
"Different means of EC have been demonstrated to be generally safe and well tolerated."	( Consequences of emergency contraceptives: the adverse effects. Chabbert-Buffet, N; Daraï, E; Keller, V; Thomin, A, 2014)	0.4
" An easy access could diminish unwanted pregnancies; however, there is a risk of misuse and, in any case, of developing some adverse events."	( Emergency contraceptive pill safety profile. Comparison of the results of a follow-up study to those coming from spontaneous reporting. Carvajal, A; García Ortega, P; García Sevillano, L; Martín Arias, LH; Pellón, M; Sáinz, M; Treceño, C; Velasco, V, 2015)	0.42
"Out of 139 women surveyed, 113 developed any adverse event--two considered as severe; the most frequently reported events were menstrual disturbances, which accounted for 21% of all events."	( Emergency contraceptive pill safety profile. Comparison of the results of a follow-up study to those coming from spontaneous reporting. Carvajal, A; García Ortega, P; García Sevillano, L; Martín Arias, LH; Pellón, M; Sáinz, M; Treceño, C; Velasco, V, 2015)	0.42
" To determine whether LNG, UPA or COC (Yuzpe) ECPs are safe for women with certain characteristics or medical conditions, we searched the PubMed and Cochrane databases for articles published from date of inception until May 2015 pertaining to the safety of LNG, UPA or Yuzpe ECP use."	( Safety data for levonorgestrel, ulipristal acetate and Yuzpe regimens for emergency contraception. Curtis, KM; Jatlaoui, TC; Riley, H, 2016)	0.43
", ulipristal acetate pills, levonorgestrel pills, and the copper-IUD), carry only mild side effects and serious adverse events are essentially unknown."	( The safety of available and emerging options for emergency contraception. Lee, JK; Schwarz, EB, 2017)	0.46
"9%; menstrual irregularity is the most common adverse effect (strength of recommendation [SOR]: B, Cochrane review of lower-quality trials)."	( Are oral emergency contraceptives a safe and effective form of long-term birth control? Hooper-Lane, C; Kraus, C, 2017)	0.46
" Main outcome measure The survey focused on the utilization of emergency contraceptives without a prescription in Germany, and on the pharmacists' experiences with (potential) problems and concerns regarding safe use."	( Trends in dispensing oral emergency contraceptives and safety issues: a survey of German community pharmacists. Freudewald, L; Ganso, M; Said, A; Schulz, M, 2019)	0.51
"This systematic review and meta-analysis aimed to summarize current evidence regarding the adverse events, and their prevalence, reported during the use of oral levonorgestrel emergency contraceptives."	( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive. Leelakanok, N; Methaneethorn, J, 2020)	0.56
"Four electronic databases and the US FDA Adverse Event Reporting System (FAERS) Public Dashboard were searched."	( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive. Leelakanok, N; Methaneethorn, J, 2020)	0.56
"A total of 47 articles were included in this systematic review, from which it was shown that most of the adverse reactions were common and not serious."	( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive. Leelakanok, N; Methaneethorn, J, 2020)	0.56
"The most common adverse effects of levonorgestrel were not serious."	( A Systematic Review and Meta-analysis of the Adverse Effects of Levonorgestrel Emergency Oral Contraceptive. Leelakanok, N; Methaneethorn, J, 2020)	0.56

Excerpt	Reference	Relevance
"A pharmaceutical and pharmacokinetic study was carried out on levonorgestrel tablets from two different sources (Hungarian- and Chinese-made)."	( Comparative cross-over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel. Fotherby, K; He, CH; Liao, DL; Matlin, SA; Shi, YE; Van Look, PF; Vince, PM; Xu, JQ; Zhu, YH, 1990)	0.28
" In view of the vast clinical applications and interactions of steroidal oral contraceptives with commonly used therapeutic agents, the interaction potential of certain concomitantly administered therapeutic agents was investigated in terms of postcoital contraceptive efficacy (pharmacological) and the pharmacokinetic profile of centchroman in female Sprague-Dawley rats."	( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006)	0.33
" Pharmacokinetic interaction was studied in normal female rats with or without coadministered drugs."	( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006)	0.33
" In pharmacokinetic interaction studies, most of the therapeutic agents affected the rate and extent of absorption of centchroman."	( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006)	0.33
"The study was intended to investigate the effect of concomitant administration of antimalarial drug (pyrimethamine or arteether) on pharmacokinetic and post coitus contraceptive efficacy of ormeloxifene in female Sprague-Dawley rats."	( Effect of arteether and pyrimethamine coadministration on the pharmacokinetic and pharmacodynamic profile of ormeloxifene. Jaiswal, S; Lal, J; Sharma, A; Shukla, M, 2017)	0.46
" Mean bioavailable LNG Cmax was lower in obese (7."	( Pharmacokinetics of the 1.5 mg levonorgestrel emergency contraceptive in women with normal, obese and extremely obese body mass index. Jusko, WJ; Molins, EAG; Natavio, M; Nelson, A; Stanczyk, FZ, 2019)	0.51

Excerpt	Reference	Relevance
"The availability of a medical mode of termination of early pregnancy by the administration of RU486, an antiprogesterone alone, or in combination with one of the PG analogues significantly reduces the maternal morbidity and mortality associated with the classical surgical abortion."	( Mifepristone (RU486) alone or in combination with a prostaglandin analogue for termination of early pregnancy: a review. Avrech, OM; Bukovsky, I; Caspi, E; Golan, A; Weinraub, Z, 1991)	0.28
"5 mg/kg combined with anordrin 2 mg/kg when given on d 6-8 of pregnancy."	( [Antifertility effects of RU-486 in combination with anordrin in rats]. Lin, ZM; Liu, GM; Qian, YX; Shen, PJ; Shen, QC; Xu, RY, 1989)	0.28
"The study purpose was to obtain additional clinical experience with 200 mcg of ethinyl estradiol combined with 2 mg dl-norgestrel as an emergency postcoital contraceptive."	( A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent. Rademaker, AW; Smith, RP; Yuzpe, AA, 1982)	0.26
"The effectiveness of mifepristone, onapristone, and ORG 31806 alone or in combination with anordiol to terminate pregnancy in the rat was evaluated."	( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat. Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997)	0.3
"The pregnancy termination potency of varying doses of mifepristone, onapristone, and ORG 3806--alone and in combination with the estrogenic/antiestrogenic compound anordiol--was evaluated in adult rats."	( Comparative effectiveness of three antiprogestins alone and in combination with anordiol in terminating pregnancy in the rat. Bardin, CW; Dao, B; Koide, SS; Li, XJ; Vanage, G, 1997)	0.3
" In 2016, the label of LNG was updated based on a drug-drug interaction (DDI) study showing a significant decrease in LNG exposure when co-administered with efavirenz, a known CYP3A4 inducer."	( Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. Bourguignon, L; Capelle, A; France, M; Goutelle, S; Le Corvaisier, C; Tod, M, 2021)	0.62

Excerpt	Reference	Relevance
" Absorption and bioavailability of the Hungarian-made tablets were greater as evidenced by higher serum concentrations of levonorgestrel, a greater area under the concentration-time curve during the first 24 hours, and a more marked suppressive effect on SHBG levels."	( Comparative cross-over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel. Fotherby, K; He, CH; Liao, DL; Matlin, SA; Shi, YE; Van Look, PF; Vince, PM; Xu, JQ; Zhu, YH, 1990)	0.28
" Following this initial explorative phase, keeping in mind that an antifertility agent must be highly effective over a period of time sufficiently long to block a dynamic process such as pregnancy, selected compounds were studied in depth in order to determine the relationships between their bioavailability and their effectiveness."	( A new class of non-hormonal contragestational agents: pharmacodynamic-pharmacokinetic relationships. Assandri, A; Galliani, G; Omodei-Salé, A, 1982)	0.26
" In other pharmacokinetic parameters, clearance (CL) remained unchanged; however, there was decrease in bioavailability (F) and volume of distribution (V(d)) in some situations."	( Effect of concurrently coadministered drugs on the pharmacokinetic/pharmacodynamic profile of centchroman, a nonsteroidal oral contraceptive, in rats. Gupta, RC; Kumar, V; Lal, J; Singh, MM, 2006)	0.33
" Moreover, the area under the curve of EE and MPA revealed an increase in bioavailability after transdermal administration as compared to oral route."	( Development and evaluation of matrix type transdermal patch of ethinylestradiol and medroxyprogesterone acetate for anti-implantation activity in female Wistar rats. Agrawal, SS; Pruthi, JK, 2011)	0.37

Excerpt	Relevance	Reference
" This dosage schedule called for 4 tablets over 12 hours, and the clinician claims that this schedule avoids some of the semantic difficulties associated with the usual treatment of 50-60 tablets of estrogen over 5 days."	( An alternative to the use of high-dose estrogens for postcoital contraception. Schilling, LH, 1979)	0.26
" This task calls for chronic dosing and the accompanying problem of eventual liver involvement and hypertrophy of the secondary accessory sex organs."	( Contraceptive technology in the future. Corbin, A, 1979)	0.26
" High dosage of progestins are in common use in the treatment of abortus imminens."	( [Current status of gestagen administration. 2. Gestagen therapy in the area of reproduction]. Völker, W, 1977)	0.26
" 189 campus women received the dosage of 2 tablets in 12 hours, given within 72 hours of unprotected intercourse."	( Post-coital contraception using d1-norgestrel/ethinyl estradiol combination. Ross, A; Smith, RP, 1978)	0.26
" All compounds were active anti-implantational agents, varying in required dosage from 4 mug to 2000 mug (total dosage over 4 days)."	( Post-coital contraceptive activity and estrogen receptor binding affinity of phenolic steroids. Müller, RE; Wotiz, HH, 1977)	0.26
"5 mg/kg body weight) of the compound administered on days 1, 2 or 3 of pregnancy or multiple dosing (0."	( Biological profile of 2-[4-(2-N-piperidinoethoxy) phenyl]-3-phenyl (2H) benzo (b) pyran--a potent antiimplantation agent in rat. Dhar, JD; Duran, S; Kapil, RS; Setty, BS, 1991)	0.28
" Teichmann, who indicates that 3-phase preparations under proper dosage prevent conception by hindering ovulation."	( [Headlines]. Uhl, D, 1989)	0.28
" The recommended dosage is 2 tablets taken 12 hours apart, preferably within 12-24 hours, and no later that 72 hours, after intercourse."	( Ovral as a "morning-after" contraceptive. , 1989)	0.28
"The effects of two cyclically administered, triphasic, combined low dosage oestrogen and progestogen oral contraceptives on haemostasis have been compared in a longitudinal study, over 6 months, in 26 healthy females aged 16-30 years."	( A comparison of the effects of two triphasic oral contraceptives on haemostasis. Cohen, H; Gillmer, MD; Machin, SJ; Mackie, IJ; Walshe, K, 1988)	0.27
" Thus, the fact of adding on the 4th day of the RU 486 treatment a weak dosage of synthetic prostaglandin equal to 1/6 of that used alone when inducing abortions made a clear improvement in the results possible."	( Fertility control in women: results with RU 486 by the end of 1985. Baulieu, E, 1986)	0.27
"Ethinylestradiol (EE), at a dosage of 5 mg/day for 5 consecutive days (5 mg EE), has generally been used for interception."	( A comparison of high-dose estrogens versus low-dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women. Haspels, AA; Van Santen, MR, 1985)	0.27
"Ethinyl estradiol (EE), at a dosage of 5 mg/day for 5 consecutive days (5 mg EE) has generally been used for interception."	( A comparison of high-dose estrogens versus low-dose ethinylestradiol and norgestrel combination in postcoital interception: a study in 493 women. Haspels, AA; Van Santen, MR, 1985)	0.27
" In certain postcoital dosing regimens, 2 analogs were more active in preventing or terminating pregnancy in rats than would have been predicted on the basis of their estrogenicity."	( Potential antifertility agents. 3. Substituted dibenzothiophenecarboxylic acids and derivatives. Bialy, G; Bierwagen, ME; Crenshaw, RR; Jenks, TA; Luke, GM, 1972)	0.25
" The recommended oral dosage is 25 mg twice daily for 5 consecutive days, begun within 72 hours after sexual exposure."	( Diethylstilbestrol as a "morning after" contraceptive. , 1973)	0.25
" With an increase in the dosage of the extract, the percentage of implantation failure increased."	( Flowers of Hibiscus rosa-sinensis, a potential source of contragestative agent: I. effect of benzene extract on implantation of mouse. Bhattacharya, K; Kabir, SN; Pakrashi, A; Pal, AK, 1984)	0.27
" Half the dosage was administered immediately upon entry into the study and the remainder 12 hours later."	( A multicenter clinical investigation employing ethinyl estradiol combined with dl-norgestrel as postcoital contraceptive agent. Rademaker, AW; Smith, RP; Yuzpe, AA, 1982)	0.26
" Dose-response curves can be prepared from these average results, and the relative in vivo effectiveness of the spermicides can be determined."	( Postcoital, Vaginal, spermicidal potency of formulations: the Macaca arctoides (stumptailed macaque) as animal model. Hahn, DW; Zaneveld, LJ; Zatuchni, B, 1981)	0.26
" Most of the clinical trials have studied its efficacy in the termination of early pregnancy when used in conjunction with a low dosage of a prostaglandin analogue."	( Mifepristone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Brogden, RN; Faulds, D; Goa, KL, 1993)	0.29
" If indeed it has occurred, and the patient has given written consent, the clinicians administers 2 times the dosage of 1 OC to the patient and a repeat dose 12 hours later."	( Six years of clinical experience using postcoital contraception in college women. Buttermore, S; Nolan, C, 1993)	0.29
" In our case, we describe a CVA due to occlusion of the common carotid artery after an acute massive overdose of estrogens due to error of dosage when using Yuzpe's system or emergency post-coital therapy."	( [Occlusion of the right common carotid artery due to oral estrogen overdose]. Escudero, D; Sánchez-Ojanguren, J; Zapata, A, 1998)	0.3
"Emergency contraceptive devices are most often applied either in combination with estrogen and progesterone or only progesterone in high dosage (0."	( [Emergency contraception]. Draca, P, )	0.13
" Serial blood samples were drawn over 72 h after dosing in a fasting state."	( Pharmacokinetics of levonorgestrel 0.75 mg tablets. Duncan, G; Gabelnick, H; Kook, K, 2002)	0.31
"The observation that estrogens in sufficient dosage given postcoitally may prevent implantation of the ovum have led to studies regarding practical clinical application."	( Post-coital oral contraception. Morris, JM; Van Wagenen, G, 1966)	0.24
" The dosage schedule is 2 tablets at once followed by 2 tablets after 12 hours."	( Statement on postcoital contraception. , 1981)	0.26
" The dosage was either 5 mg of stilboestrol 5 times daily for 5 days, or 1 mg of ethinyloestradiol twice daily for 5 days."	( The "morning-after pill"--a preliminary report. Haspels, AA, 1969)	0.25
" The recommended regimen consists of six tablets of Ovral (two taken immediately, two more in 12 hours) or 12 tablets of Lo/Ovral, Nordette, or Levlen (four taken immediately, repeat dosage in 12 hours)."	( Emergency contraceptive pills (ECP) protocol. , 1994)	0.29
" The other OCs require a dosage of four pills each time."	( FDA finds emergency postcoital contraception safe and effective. , 1996)	0.29
" Administration and dosage of the various agents is to be specified by a doctor according to the particular method, and to the state of health of the patient."	( [Pharmacological aspects of oral contraceptives (author's transl)]. Simon, P; Soubrie, C; Weil-levy, C, 1980)	0.26
" Among new preparations, the combination of 2 mg cyproterone acetate and 50 mcg of ethinyl estradiol (EE) has been shown in multicenter European studies to have good effects on acne and satisfactory acceptance despite some hyperestrogenic secondary effects, which may be improved by a new dosage schedule."	( [Current issues in contraception]. Audebert, AJ, 1985)	0.27
" In countries where emergency contraception is only available by prescription, providers should offer an advance prescription or supply (where available), and use newer dosing regimens for levonorgestrel-only emergency contraception to increase adherence and efficacy."	( Emergency contraceptive pills: a review of the recent literature. Conard, LA; Gold, MA, 2004)	0.32
" Although most had accurate knowledge about the method's dosing schedule, side effects and mechanism(s) of action, more than half erroneously believed that repeated use posed health risks."	( Pharmacists' knowledge and perceptions of emergency contraceptive pills in Soweto and the Johannesburg Central Business District, South Africa. Blanchard, K; Harrison, T; Sello, M, 2005)	0.33
" Women refrained from nursing for 72 h after dosing and fed their infants with milk frozen beforehand."	( Levonorgestrel pharmacokinetics in plasma and milk of lactating women who take 1.5 mg for emergency contraception. Bouyer, J; Caviedes, R; Forcelledo, ML; Gainer, E; Lillo, S; Massai, R; Reyes, V; Villarroel, C, 2007)	0.34
" The vast majority (97%) of the respondents were aware of the dosing schedule of the available ECP."	( Knowledge and attitudes of pharmacists regarding over-the-counter emergency contraception in South-Eastern Hungary. Bártfai, G; Szöllosi, AP; Szucs, M, 2010)	0.36
" Both Phase III clinical trials found that UPA does not lose efficacy within the 120-h dosing interval."	( Ulipristal acetate: a new emergency contraceptive. Bulloch, MN; Sullivan, JL, 2011)	0.37
"UPA, at the dosage used for EC, does not affect human embryo implantation process, in vitro."	( Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Berger, C; Boggavarapu, NR; Gemzell-Danielsson, K; Lalitkumar, PG; Menezes, J, 2015)	0.42
"This study provides new insights on the mechanism of action of UPA on human embryo implantation, demonstrating that UPA in a dosage used for EC does not affect embryo viability and the implantation process of embryo."	( Effects of ulipristal acetate on human embryo attachment and endometrial cell gene expression in an in vitro co-culture system. Berger, C; Boggavarapu, NR; Gemzell-Danielsson, K; Lalitkumar, PG; Menezes, J, 2015)	0.42
" Different methods have varying modes of action, time frame of efficacy, dosage schedule and unwanted effects."	( Emergency contraception: which is the best? Mittal, S, 2016)	0.43
" We also included data from 2 subjects who experienced rupture prior to COC dosing in the analysis."	( Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study. Edelman, AB; Hennebold, JD; Jensen, JT; McCrimmon, S; Messerle-Forbes, M; O'Donnell, A, 2018)	0.48
" Moderate to severe DDI were predicted in 17 cases with CYP3A4 inducers, and dosage adjustments were suggested."	( Drug interactions between emergency contraceptive drugs and cytochrome inducers: literature review and quantitative prediction. Bourguignon, L; Capelle, A; France, M; Goutelle, S; Le Corvaisier, C; Tod, M, 2021)	0.62

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	477 (26.62)	18.7374
1990's	339 (18.92)	18.2507
2000's	640 (35.71)	29.6817
2010's	276 (15.40)	24.3611
2020's	60 (3.35)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	72 (3.67%)	5.53%
Reviews	276 (14.07%)	6.00%
Case Studies	33 (1.68%)	4.05%
Observational	3 (0.15%)	0.25%
Other	1,577 (80.42%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (203)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Open-label Study to Investigate the Potential Pharmacokinetic Interaction of Perampanel With Oral Contraceptives in Healthy Female Subjects [NCT01209858]	Phase 1	48 participants (Actual)	Interventional	2010-03-31	Completed
Bioavailability of a Formulation of Levonorgestrel and Ethinyl Estradiol 15.0 mg/0.03 mg Coated Tablets With Regards to the Marketed Reference Product [NCT05282940]	Phase 1	36 participants (Actual)	Interventional	2022-02-26	Completed
Phase II Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer [NCT03225547]	Phase 2	74 participants (Anticipated)	Interventional	2018-02-12	Active, not recruiting
An Open Label Study of 400 mcg Sublingual Misoprostol Following Mifepristone 200 mg for Abortion up to 63 Days LMP [NCT01173003]		688 participants (Actual)	Interventional	2009-06-30	Completed
Pharmacokinetics of Levonorgestrel and Ulipristal Acetate Emergency Contraception in Women With Normal and Obese Body Mass Index [NCT02689804]	Phase 4	34 participants (Actual)	Interventional	2015-07-10	Completed
A RANDOMIZED, PHASE II STUDY OF ENZALUTAMIDE, ENZALUTAMIDE WITH MIFEPRISTONE, and TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH AR+ METASTATIC TRIPLE-NEGATIVE OR ER-LOW BREAST CANCER [NCT06099769]	Phase 2	201 participants (Anticipated)	Interventional	2023-10-18	Recruiting
A Prospective, Randomized Controlled Trial Comparing the Use of Dienogest and Combined Oral Contraceptive Pills (Microgynon) to Reduce the Risk of Recurrence of Endometriotic Cyst After Conservative Surgery [NCT02385448]	Phase 4	144 participants (Anticipated)	Interventional	2015-02-28	Recruiting
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC) [NCT02354170]	Phase 2	16 participants (Actual)	Interventional	2015-01-31	Completed
Mifepristone and Misoprostol Versus Misoprostol Alone for Missed Abortion: A Randomized-controlled Trial [NCT02342002]	Phase 4	416 participants (Anticipated)	Interventional	2015-01-31	Terminated(stopped due to lack of funding)
Alternative Provision of Medication Abortion Via Pharmacy Dispensing [NCT03320057]	Phase 4	326 participants (Actual)	Interventional	2018-06-01	Completed
A Non-randomised, Open-label Phase I Trial to Evaluate the Effect of BI 456906 at Different Dose Levels of Multiple Subcutaneous Doses in a Titration Scheme on the Single Dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Oth [NCT05896384]	Phase 1	24 participants (Anticipated)	Interventional	2023-12-07	Not yet recruiting
An Outpatient Medical Abortion Regimen With Mifepristone and Two Doses of Misoprostol at 71-77 and 78-84 Days of Pregnancy [NCT05119439]	Phase 4	23 participants (Actual)	Interventional	2022-10-07	Terminated(stopped due to Enrollment)
A Prospective, Randomized, Double-blind Parallel-arm, Placebo-controlled Study to Assess the Effects on Ovarian Activity of a Combined Oral Contraceptive Pill When Preceded by the Intake of ellaOne® (Ulipristal Acetate 30 mg) or Placebo. [NCT01569113]	Phase 4	76 participants (Actual)	Interventional	2012-03-31	Completed
Improving Access to Abortion in the Republic of Georgia [NCT04458558]	Phase 4	120 participants (Anticipated)	Interventional	2020-06-30	Recruiting
A Phase I Adaptive Dose, Double-Blind, Placebo-Controlled, SAD and MAD Study to Measure the Safety, Tolerability, Pharmacokinetics and Pharmacological Effects of Orally Administered CORT125134 in Healthy Subjects [NCT03508635]	Phase 1	130 participants (Actual)	Interventional	2014-09-30	Completed
Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Georgia: A Study of 400 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 63 Days Gestation [NCT02398838]		622 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized, Placebo-Controlled, Double-Blind, Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane®) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer [NCT02788981]	Phase 2	64 participants (Anticipated)	Interventional	2017-03-28	Active, not recruiting
A Pilot Study on the Safety and Efficacy of Mifepristone for the Prevention of Relapses of Alcohol Drinking [NCT02243709]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2014-09-30	Completed
Outpatient Medical Abortion With Mifepristone and Misoprostol Through 77 Days of Gestation: A Non-inferiority Trial [NCT02314754]	Phase 4	719 participants (Actual)	Interventional	2014-12-31	Completed
Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST) [NCT05772169]	Phase 4	1,000 participants (Anticipated)	Interventional	2023-03-31	Recruiting
Open Label, One-way Crossover Study to Assess the in Vivo Formation of Ethinylestradiol Following Single Intramuscular Administration of 200 mg Norethisterone Enantate Compared to Ethinylestradiol Pharmacokinetics After Multiple Doses of a Combined Oral C [NCT02170038]	Phase 1	16 participants (Actual)	Interventional	2014-06-30	Completed
A Randomized, Double-blind, 2-Period, 2-Sequence Crossover Phase I Study With a 1 Month run-in Period to Examine the Effect of Cladribine Tablets on the PK of a Monophasic Oral Contraceptive Containing Ethinyl Estradiol and Levonorgestrel (Microgynon®) in [NCT03745144]	Phase 1	24 participants (Actual)	Interventional	2019-01-17	Completed
An Open, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 1356 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel [NCT02175394]	Phase 1	18 participants (Actual)	Interventional	2008-07-31	Completed
Randomized Controlled Trial of Mifepristone Versus Laminaria for Cervical Ripening In Midtrimester Induction [NCT00383032]		72 participants	Interventional	2004-01-31	Completed
Investigation of the Effect of Subcutaneously Co-administered Semaglutide and NNC0480-0389 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) in Healthy Postmenopausal Females [NCT05153564]	Phase 1	27 participants (Actual)	Interventional	2021-12-13	Completed
A Multicenter Randomized Clinical Trial of Mifepristone Versus GnRHa for the Treatment of Adenomyosis [NCT05151016]	Early Phase 1	140 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
The Effect of a Progesterone Receptor Modulator on Breast Tissue in Women With BRCA-1 and -2 Mutations - a Placebo Controlled RCT. [NCT01898312]	Phase 2	45 participants (Actual)	Interventional	2013-09-30	Completed
Cervical Prostaglandin EP3 Receptor mRNA Expression 48 Hours After Administration of Mifepristone [NCT01224509]		18 participants (Actual)	Interventional	2004-09-30	Terminated(stopped due to Longer than expected recruitment period.)
A Biomarker Study of Mifepristone in Early Stage Breast Cancer [NCT01138553]	Early Phase 1	4 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Inadequate subject accrual)
Efficacy of Mifepristone in Males With Type 2 Diabetes Mellitus [NCT03052400]	Phase 2	8 participants (Actual)	Interventional	2017-02-03	Terminated(stopped due to End of Funding)
The Effect of Multiple Doses of BI 425809 on the Pharmacokinetics of Multiple Doses of a Combination of Ethinylestradiol and Levonorgestrel Following Oral Administration in Healthy Premenopausal Female Subjects (an Open-label, Two-period, Fixed Sequence D [NCT05613777]	Phase 1	19 participants (Actual)	Interventional	2022-11-24	Completed
Evaluation of Efficacy of Two Therapeutic Strategies for Cervical Maturation Before Medical Termination: Mechanical Plus Medicinal Maturation vs Medicinal Maturation Alone [NCT03194126]		120 participants (Actual)	Interventional	2018-02-11	Completed
A Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical Cushings [NCT00721201]	Phase 1/Phase 2	6 participants (Anticipated)	Interventional	2008-11-30	Completed
A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, 2-arm Study to Show Superiority of the Oral Contraceptive SH T00658ID Over Microgynon on Hormone Withdrawal-associated Symptoms After 6 Cycles of Treatment [NCT00778609]	Phase 3	449 participants (Actual)	Interventional	2008-12-31	Completed
"Evaluating the Safety, Acceptability and Feasibility of an Outpatient Day Procedure Service Documenting the Roles of Health Workers in the Provision of Medical Abortion at 13-18 Weeks Gestation" [NCT03346629]	Phase 4	230 participants (Actual)	Interventional	2017-12-01	Completed
Comparison of Efficacy and Safety of Sequential Use of Mifepristone and Misoprostol vs Misoprostol Alone in Women With Early Pregnancy Loss: Randomized Controlled Trial [NCT05124314]	Phase 4	220 participants (Anticipated)	Interventional	2021-10-27	Recruiting
Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome [NCT01371565]	Phase 3	4 participants (Actual)	Interventional	2010-11-30	Completed
RESET-medication: Glucocorticoid Receptor (GR) Blockade as Diseasemodifying Treatment for Depression With Childhood Trauma [NCT05217758]	Phase 2	158 participants (Anticipated)	Interventional	2021-12-09	Recruiting
A Randomised Placebo-controlled Trial of Mifepristone and Misoprostol Versus Misoprostol Alone in the Medical Management of Missed Miscarriage [NCT03065660]	Phase 3	711 participants (Actual)	Interventional	2017-09-20	Completed
Mifepristone 5 mg Versus 10 mg for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. [NCT00712595]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2007-01-31	Completed
A Phase I, Open-Label, Fixed-Sequence Study to Determine the Effect of Single and Multiple Oral Doses of CORLUX (TM) (Mifepristone) on the Pharmacokinetics of a Single Oral Dose of Fluvastatin (a CYP2C9 Probe) in Healthy Volunteers [NCT00752843]	Phase 1	20 participants (Actual)	Interventional	2008-09-30	Completed
Uptake and Acceptability of Home-use of Mifepristone for Medical Abortion [NCT00994734]		615 participants (Actual)	Interventional	2009-05-31	Completed
Mifepristone 5 mg Versus 10 mg During 6 Months for the Treatment of Uterine Leiomyomata. A Randomized, Double Blinded Clinical Trial. [NCT00886873]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2008-05-31	Completed
Single Center, Double Blind, Randomized, Crossover Study to Investigate the Impact of the Oral Contraceptive Yasmin (30 µg EE / 3 mg DRSP) Compared to Microgynon (30 µg / 150 LNG) on Hemostasis Parameters in 40 Female Volunteers [NCT00651846]	Phase 4	43 participants (Actual)	Interventional	2003-06-30	Completed
Mifepristone Versus Osmotic Dilators in Conjunction With Misoprostol for Cervical Preparation Prior to D&E at 14-19 Weeks [NCT02679092]		0 participants (Actual)	Interventional	2016-04-30	Withdrawn(stopped due to Funding changes.)
Comparing Two Regimens for Medical Abortion: Mifepristone+Misoprostol Versus Misoprostol Alone [NCT00680394]		440 participants (Actual)	Interventional	2007-07-31	Completed
Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone [NCT00833339]	Phase 2	80 participants (Anticipated)	Interventional	2008-05-31	Recruiting
A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-day Regimen as Compared to a Monophasic Cont [NCT00933179]	Phase 2	30 participants (Actual)	Interventional	2009-06-30	Completed
Evaluation of the Efficacy, Tolerance of the Treatment, and Patient Satisfaction During the Management of an Arrested Pregnancy in the First Trimester According to the New Toulouse University Hospital Protocol [NCT05049980]		52 participants (Actual)	Interventional	2021-11-01	Completed
Microgynon Riociguat Drug Interaction Study to Investigate the Effect of Riociguat 2.5 mg 3 Times Daily Multiple-dose Treatment on the Plasma Concentrations of / Exposure to Levonorgestrel and Ethinyl Estradiol in Healthy Postmenopausal Women in a 2-fold [NCT02159326]	Phase 1	31 participants (Actual)	Interventional	2014-06-30	Completed
A Phase II Study of Treatment With Oral Mifepristone as Salvage Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Two or More Previous Chemotherapy Regimens [NCT02642939]	Phase 2	3 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Lack of enrollment)
Glucocorticoid Antagonists in Heavy Drinkers: Effects on fMRI Connectivity, Withdrawal and Drinking [NCT02989662]		150 participants (Anticipated)	Interventional	2016-02-29	Recruiting
A Randomized, Double-blind Placebo-controlled Crossover Trial of Mifepristone in Gulf War Veterans With Chronic Multisymptom Illness [NCT00691067]	Phase 4	65 participants (Actual)	Interventional	2008-05-31	Completed
Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial [NCT00784186]		120 participants (Actual)	Interventional	2008-08-31	Completed
Comparison Between Misopristol and Pitocin After Mifepristone Preparation for Second Trimeter Abortion [NCT00784797]	Phase 4	145 participants (Actual)	Interventional	2009-01-31	Completed
Understanding Gulf War Illness: An Integrative Modeling Approach [NCT04255498]	Phase 1	20 participants (Anticipated)	Interventional	2017-10-30	Recruiting
Pilot Study of an Ambulatory Medical Abortion Service at 13-18 Weeks of Gestation in Colombia [NCT04063904]	Phase 4	16 participants (Actual)	Interventional	2019-10-16	Terminated(stopped due to Difficulties with recruitment, COVID 19 pandemic)
Mifepristone and Misoprostol Versus Misoprostol Alone for Treatment of Fetal Death at 14-28 Weeks of Pregnancy: A Randomized, Placebo-controlled Double-blinded Trial [NCT02633761]	Phase 3	200 participants (Anticipated)	Interventional	2015-04-01	Terminated(stopped due to Lack of funding)
The Effect of Vaginal Mifepristone on Reduction of Uterine Fibroids Size and the Symptoms Associated With the Fibroids - Pilot Study (Phase IIa) [NCT00881140]	Phase 2	30 participants (Actual)	Interventional	2009-04-30	Completed
Medical Termination of Pregnancy Due to Emergency Contraception Failure: A Randomized Trial Comparing Mifepristone Combined Misoprostol and Misoprostol Alone. [NCT00677755]		394 participants (Actual)	Interventional	2004-10-31	Completed
A Randomized Controlled Trial to Compare Sublingual and Buccal Misoprostol Regimens After Mifepristone for Termination of Pregnancy 13 - 21 Weeks From Last Menstrual Period (LMP) [NCT02708446]	Phase 4	320 participants (Anticipated)	Interventional	2014-05-31	Recruiting
Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14-21 Weeks LMP): A Randomized-controlled Double-blinded Trial [NCT00957346]	Phase 3	20 participants (Anticipated)	Interventional	2011-02-28	Terminated
Mifepristone and Misoprostol Versus Misoprostol Alone for Mid-trimester Termination of Pregnancy (14 - 21 Weeks LMP): A Randomized-controlled Double-blinded Trial [NCT00969982]		238 participants (Actual)	Interventional	2009-06-30	Completed
Multi-center, Double-blind, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive Containing Estradiol Valerate and Dienogest (SH T00658ID) Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (Micr [NCT00764881]	Phase 3	217 participants (Actual)	Interventional	2009-01-31	Completed
The Effectiveness, Safety, and Acceptability of Home-administered Medical Abortion at Gestational Age of 8 to ≤9 Weeks Versus >9 to ≤12 Weeks: A Prospective Cohort Study in Mexico City [NCT02745093]	Phase 4	648 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
A Pilot Study of the Acceptability and Feasibility of an Out-patient Regimen of Medical Abortion With Mifepristone and 400 mcg Sublingual Misoprostol at 71-77 and 78-84 Days Gestation [NCT02720991]	Phase 4	50 participants (Actual)	Interventional	2014-07-31	Completed
Pre-treatment With Mifepristone in Patients With Mirena for Optimizing Bleeding Pattern in Pre-menopausal Women [NCT01931657]	Phase 2	60 participants (Anticipated)	Interventional	2013-08-31	Completed
Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer [NCT02046421]	Phase 1	31 participants (Actual)	Interventional	2013-11-30	Completed
An Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome [NCT00569582]	Phase 3	50 participants (Actual)	Interventional	2007-12-31	Completed
A Phase II Evaluation of Mifepristone in the Treatment of Recurrent or Persistent Epithelial Ovarian or Primary Peritoneal Carcinoma [NCT00459290]	Phase 2	24 participants (Actual)	Interventional	2007-05-31	Completed
Assessing Acceptability and Use of Medical Menstrual Regulation in the United States [NCT03972358]	Phase 2	284 participants (Anticipated)	Interventional	2020-02-12	Recruiting
Treatment of Early Pregnancy Failure [NCT00468299]		16 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to poor enrollment)
A Double-blind, Placebo-controlled Study of Mifepristone in Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT) [NCT00285818]		11 participants (Actual)	Interventional	2003-01-31	Completed
Cervical Preparation With Mifepristone Prior to Osmotic Dilators: A Randomized, Double-blind, Placebo-controlled Pilot Study [NCT03714880]	Phase 2	44 participants (Actual)	Interventional	2019-04-26	Terminated(stopped due to Slow recruitment compounded by COVID-19)
Effects of Mifepristone on Biomarkers of Metabolic Function and Neuropsychological Performance Among Middle-Aged and Older Individuals [NCT01988610]	Phase 1	23 participants (Actual)	Interventional	2013-10-31	Completed
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer. [NCT02014337]	Phase 1	37 participants (Actual)	Interventional	2014-01-31	Completed
Acceptability and Feasibility of a Simplified Medical Abortion Regimen in Kazakhstan: A Study of 600 µg Sublingual Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation [NCT02018796]		290 participants (Actual)	Observational	2013-10-31	Completed
Acceptability and Feasibility of a Demedicalized Medical Abortion Regimen in the Caucasus [NCT02219100]		613 participants (Actual)	Interventional	2010-11-30	Completed
Early Versus Delayed Insertion of Nexplanon® at Medical Abortion - a Randomized Controlled Equivalence Trial. [NCT01920022]	Phase 4	551 participants (Actual)	Interventional	2013-10-31	Completed
A Pilot Study of Mifepristone Followed by Misoprostol in Women Undergoing Second Trimester Abortion [NCT00592215]	Phase 1	0 participants (Actual)	Interventional	2008-03-31	Withdrawn
Hypothalamic-Pituitary-Adrenal (HPA)/Dopamine Axis in Psychotic Depression [NCT00867360]	Phase 3	10 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to Insufficient recruitment.)
Non-surgical Alternatives to Treatment of Failed Medical Abortion: A Randomized Controlled Double-blind Trial [NCT02704481]	Phase 4	16 participants (Actual)	Interventional	2016-06-01	Terminated(stopped due to Funding mechanism compromised)
The Effect of Atazanavir/Cobicistat on the Pharmacokinetics of an Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (Microgynon 30®) in Healthy Women [NCT02697851]	Phase 1	13 participants (Actual)	Interventional	2016-07-31	Terminated(stopped due to "Insufficient enrolment and business reasons")
A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females [NCT02845219]	Phase 1	25 participants (Actual)	Interventional	2016-07-31	Completed
Mifepristone and Misoprostol for the Treatment of Early Pregnancy Failure: a Pilot Clinical Trial [NCT00177372]	Phase 4	30 participants (Actual)	Interventional	2005-01-31	Completed
Feasibility and Acceptability of Dispensing Mifepristone Via Mail Order Pharmacy [NCT03913104]	Phase 4	538 participants (Actual)	Interventional	2020-01-05	Active, not recruiting
Comparison of the Effectiveness of Abortive Measures From the Administration of Mifegyne and Cytotec at One and Two Visits [NCT00920465]	Phase 3	200 participants (Anticipated)	Interventional	2009-06-30	Recruiting
The Extended Gestational Age Medical Abortion Study: The Effectiveness of Medical Abortion With Mifepristone and Misoprostol at 57-63 Days Versus 64-70 Days Gestation [NCT00997347]	Phase 4	1,400 participants (Actual)	Interventional	2009-07-31	Completed
A Randomised, Double-blind, Two-way Crossover Study to Determine the Effects of Co-administration of AZD6140 and Nordette® (Combination of Levonorgestrel and Ethinyl Estradiol) After Multiple Oral Doses in Healthy Female Volunteers [NCT00685906]	Phase 1	24 participants (Anticipated)	Interventional	2008-04-30	Completed
[NCT00206193]		0 participants	Observational		Recruiting
The Effect of Preoperative Treatment With Mifepristone on Uterine Fibroids and Breast Tissue [NCT00579475]	Phase 1	30 participants (Actual)	Interventional	2004-11-30	Completed
The Acceptability of an Out-patient Regimen of Medical Abortion With Mifepristone and 800 Mcg Misoprostol Administered Buccally or Sublingually at 78-84 Days Gestation: Two Pilot Studies [NCT01856985]	Phase 4	50 participants (Actual)	Interventional	2013-04-30	Completed
Mifepristone and Misoprostol for Undesired Pregnancy of Unknown Location: A Randomized Pilot Study of Misoprostol Dosing [NCT05839899]	Phase 3	50 participants (Anticipated)	Interventional	2023-08-30	Recruiting
COMPARATIVE STUDY OF EFFECTS BETWEEN LETROZOLE PLUS MISOPROSTOL AND MIFEPRISTONE PLUS MISOPROSTOL IN TERMINATING NON-VIABLE FIRST TRIMESTER PREGNANCIES [NCT05304273]	Phase 3	120 participants (Anticipated)	Interventional	2022-05-05	Recruiting
Mifepristone Treatment for Breast Cancer Patients Expressing Levels of Progesterone Receptor Isoform A (PRA) Higher Than Those of Isoform B (PRB): Neoadjuvant Therapy. [NCT02651844]		20 participants (Actual)	Interventional	2016-04-30	Completed
A Randomized Phase I Trial of Nanoparticle Albumin Bound Paclitaxel (Nab-paclitaxel, Abraxane) With or Without Mifepristone for Advanced Breast Cancer [NCT01493310]	Phase 1	9 participants (Actual)	Interventional	2011-11-30	Completed
Phase II Study of Mifepristone (RU-486) in the Treatment of PR Positive Advanced/Recurrent Endometrioid Adenocarcinoma and Low Grade Endometrial Stromal Sarcoma (LGESS) [NCT00505739]	Phase 2	13 participants (Actual)	Interventional	2001-09-30	Completed
Mifepristone Outpatient Labour Induction [NCT05177510]	Phase 3	400 participants (Anticipated)	Interventional	2023-08-25	Recruiting
Mifepristone After Trauma to Enhance Resilience [NCT00554177]	Phase 1	5 participants (Actual)	Interventional	2007-09-30	Completed
The Use of Letrozole or Mifepristone for Pretreatment of Medical Termination of Pregnancy: a Randomized, Non-inferiority Trial [NCT05341817]	Phase 4	144 participants (Anticipated)	Interventional	2022-11-22	Recruiting
An Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome [NCT00936741]	Phase 3	30 participants (Actual)	Interventional	2009-07-31	Completed
A Randomized, Double-blind, Parallel-group, Multi-center Study to Investigate the Pharmacodynamics and Pharmacokinetics of a Combined Oral Contraceptive Containing Levonorgestrel (LNG) and Ethinylestradiol (EE) When Given Together With Vilaprisan Over 3 M [NCT03210246]	Phase 1	71 participants (Actual)	Interventional	2017-07-17	Completed
Mifepristone Tablets in the Treatment of Symptomatic Uterine Fibroids With Safety and Efficacy in Open, Multicenter Phase IV Clinical Studies [NCT03210324]	Phase 4	434 participants (Actual)	Interventional	2017-06-01	Terminated(stopped due to It is difficult to recruit enough participants)
A Pilot Study on the Combined Use of Letrozole, Miferpristone and Misoprostol in Termination of First Trimester Pregnancy up to 63 Days Gestation [NCT01475318]		50 participants (Anticipated)	Interventional	2011-10-31	Recruiting
Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda. [NCT01480778]	Phase 3	62 participants (Actual)	Interventional	2014-07-31	Completed
A Randomized, Placebo-Controlled, Phase I/II Trial of the Anti-HIV Activity and Safety of VGX-410 (Mifepristone) at Three Dose Levels in HIV-1 Infected Subjects [NCT00099645]	Phase 1/Phase 2	48 participants	Interventional		Completed
A Double-blind, Placebo-controlled Trial of the Safety and Efficacy of C-1073 (Mifepristone) as Adjunctive Therapy in Alzheimer's Disease [NCT00105105]	Phase 2	160 participants	Interventional	2003-04-30	Terminated
Medication Enhanced Rapid Therapy [NCT02099825]	Phase 1	15 participants (Actual)	Interventional	2014-01-13	Terminated(stopped due to COVID and staffing issues)
[NCT00482209]		1,220 participants (Anticipated)	Interventional	2007-05-31	Completed
An International, Double-Blind, Placebo-Controlled, Study of the Efficacy and Safety of CORLUX™ (Mifepristone) vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Psychotic Major Depression (PMD) [NCT00146523]	Phase 3	247 participants (Actual)	Interventional	2005-05-31	Completed
A Randomized, Double-Blind, Placebo-Controlled Study of Safety and Efficacy of CORLUX™ (Mifepristone) in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features [NCT00130676]	Phase 3	257 participants (Actual)	Interventional	2004-09-30	Completed
A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins [NCT00140478]	Phase 2	48 participants (Anticipated)	Interventional	2005-02-28	Completed
A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features [NCT00637494]	Phase 3	292 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to DRC recommended stopping study as it had missed its primary endpoint)
Investigation of the Effects of Mifepristone (RU486) on Stress Sensitivity and Relapse Prevention in Cocaine Dependent Patients [NCT01134198]	Phase 2/Phase 3	58 participants (Actual)	Interventional	2010-05-31	Completed
An Open-label, Two-period, Fixed-sequence Trial to Evaluate the Effect of Multiple Doses of BI 10773 on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Volunteers [NCT01328184]	Phase 1	18 participants (Actual)	Interventional	2011-04-30	Completed
Antiglucocorticoid Therapy for Cognitive Impairment in Late-life Anxiety Disorders [NCT01333098]	Phase 1/Phase 2	15 participants (Actual)	Interventional	2012-09-30	Completed
"Assessing Use Of Mifepristone After Progestin Priming For Use As Missed Period Pills" [NCT04676776]	Phase 2	139 participants (Anticipated)	Interventional	2021-01-25	Recruiting
Preliminary, Double Blind, Placebo Controlled Trial of the Effect of Glucocorticoid Receptor Antagonist Treatment on Biologic and Symptom Outcomes in Patients With Borderline Personality Disorder and Histories of Childhood Abuse [NCT01212588]	Phase 2	22 participants (Actual)	Interventional	2010-09-30	Terminated(stopped due to Funding ended)
A Two-Week, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain in Healthy Male Volunteers [NCT00455442]	Phase 2	57 participants (Actual)	Interventional	2007-03-31	Completed
Randomized Control Trial Of Mifepristone for Fibroids [NCT00133705]	Phase 3	70 participants (Actual)	Interventional	2003-07-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients Wit [NCT00128479]	Phase 3	443 participants (Actual)	Interventional	2004-09-30	Completed
Antiglucocorticoid Therapy in Bipolar Depression With Mifepristone (RU486) [NCT00043654]	Phase 2	110 participants	Interventional	2002-08-07	Completed
Increased Access to Emergency Contraceptive Pills [NCT00060463]		1,490 participants	Interventional	2002-10-31	Active, not recruiting
An International, Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features [NCT00128505]	Phase 3	104 participants (Actual)	Interventional	2005-08-31	Completed
Mifepristone vs. Laminaria Insertion for Cervical Preparation Prior to Surgical Abortion at 14-16 Weeks [NCT00986921]		50 participants (Actual)	Interventional	2009-10-31	Completed
An Open-Label Extension Study of the Safety and Tolerability of CORLUX™ (Mifepristone) for Recurrent Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features [NCT00208156]	Phase 3	87 participants (Actual)	Interventional	2005-05-31	Completed
A Placebo Controlled Study on the Efficacy of 10 mg Oral Mifepristone for the Treatment of Symptomatic Uterine Leiomyomas [NCT00219778]	Phase 2	20 participants (Anticipated)	Interventional	2004-12-31	Terminated
Prospective, Multicenter, Open-label, Uncontrolled Study to Investigate the Contraceptive Efficacy, Bleeding Patterns, and Safety of an Oral Contraceptive Containing 0.03 mg Ethinylestradiol and 0.125 mg Levonorgestrel (SH D00342A) Applied for 13 Cycles t [NCT00220324]	Phase 3	840 participants (Actual)	Interventional	2004-02-29	Completed
Glucocorticoid and Mineralocorticoid Receptor Function in Post Traumatic Stress Disorder [NCT00046553]		97 participants	Observational	2002-09-30	Completed
A Single-center, Open-label, Controlled, Randomized Study to Investigate the Impact of a Sequential Oral Contraceptive (SH T00658ID) as Compared to a Sequential Oral Contraceptive Containing Ethinylestradiol and Levonorgestrel (SH D00264A) on Plasma Lipid [NCT00185224]	Phase 2	58 participants (Actual)	Interventional	2005-03-31	Completed
Comparison Expectant With Immediate Medical Management for the Evacuation of the no Evolutionary Pregnancies Before 13 GW [NCT00190294]	Phase 4	200 participants (Actual)	Interventional	2003-04-30	Completed
Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) Secretion [NCT00422201]	Phase 2	18 participants (Actual)	Interventional	2007-05-15	Terminated
INST 0817: Compassionate Use of Mifepristone [NCT00832871]		4 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Low accrual; 4 patients enrolled between 2008-2015)
Psychophysiology of Delayed Extinction and Reconsolidation in Humans [NCT01631682]	Phase 4	186 participants (Actual)	Interventional	2010-11-30	Completed
Cervical Rippening With Antiprogesterone in Midtrimester Abortions [NCT00410345]	Phase 4	145 participants (Actual)	Interventional	2004-08-31	Completed
An Open-label Study to Evaluate the Contraceptive Efficacy and Safety of the Transdermal Contraceptive System of 17-deacetylnorgestimate and Ethinyl Estradiol With the Oral Contraceptive Triphasil. [NCT00236795]	Phase 3	1,494 participants (Actual)	Interventional	1997-01-31	Completed
A Multicenter, Randomized Comparison of Mifepristone and Misoprostol Administered Simultaneously Versus 24 Hours Apart for Abortion Through 63 Days [NCT00269568]	Phase 4	1,128 participants (Actual)	Interventional	2004-06-30	Completed
Mifepristone 2.5, 5, 10 mg Versus Placebo in the Treatment of Endometriosis [NCT02271958]	Phase 2/Phase 3	360 participants (Actual)	Interventional	2010-11-30	Completed
A Randomized Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation [NCT00286208]		1,443 participants (Actual)	Interventional	2005-08-31	Completed
Oral Mifepristone and Buccal Misoprostol Administered Simultaneously for Abortion Through 63 Days Gestation [NCT00330993]	Phase 2	120 participants	Interventional	2006-03-31	Completed
A Single Centre Open-label Randomised Controlled Trial of Long Term Pituitary Down-regulation Before in Vitro Fertilisation for Women With Endometriosis: a Pilot Study [NCT01757249]	Phase 4	5 participants (Actual)	Interventional	2013-01-31	Terminated(stopped due to Unable to recruit sufficient participants)
Medical Abortion With Mifepristone + Misoprostol (13 - 22 Weeks): A Double-blind Randomized-controlled Trial [NCT01768299]	Phase 4	504 participants (Actual)	Interventional	2013-02-28	Completed
Treatment of Uterine Myoma With 2.5 or 5 mg Mifepristone Daily During 3 Months With 9 Months Post-treatment Follow-up. Randomized Clinical Trial. [NCT01786226]	Phase 2/Phase 3	220 participants (Actual)	Interventional	2010-03-31	Terminated
Exploring a Patient-centered Approach to Mifepristone Administration in Medical Abortion [NCT01811056]		401 participants (Actual)	Interventional	2013-04-30	Completed
Acceptability and Feasibility of a Simplified Medical Abortion Service Delivery in Western Ukraine: A Demonstration Study of 800 mcg Buccal Misoprostol Following 200 mg Mifepristone for Abortion up to 70 Days Gestation [NCT02981030]	Phase 4	102 participants (Actual)	Interventional	2016-11-23	Completed
An Open-label, Two-period, Fixed-sequence, Phase I Trial to Evaluate the Effect of Multiple Doses of BI 207127 + Faldaprevir on the Multiple-dose Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Healthy Premenopausal Female Subj [NCT01941615]	Phase 1	18 participants (Actual)	Interventional	2013-11-30	Terminated
Mifepristone Versus Misoprostol for Cervical Preparation Prior to Surgical Abortion Between 11 to 15 Weeks [NCT01636063]		42 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to Poor subject enrollment)
Comparative Effectiveness of Pregnancy Failure Management Regimens [NCT02012491]	Phase 3	300 participants (Actual)	Interventional	2014-01-31	Completed
Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma [NCT03015701]	Phase 3	193 participants (Actual)	Interventional	1992-08-31	Completed
Value of Mifepristone in Eliminating the Need for a Second Set of Osmotic Dilators Prior to Dilation and Evacuation Between 19-24 Weeks: A Randomized Trial [NCT01615731]		50 participants (Actual)	Interventional	2012-05-31	Completed
A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients [NCT00255177]	Phase 2	44 participants (Actual)	Interventional	2005-11-30	Completed
Mifepristone Versus Osmotic Dilator Insertion for Cervical Preparation Prior to Surgical Abortion at 15-18 Weeks [NCT01436279]	Phase 3	50 participants (Actual)	Interventional	2011-07-31	Completed
Glucocorticoid Antagonist Treatment of Alcohol Use Disorder [NCT02179749]	Phase 2	103 participants (Actual)	Interventional	2014-09-30	Completed
Single-Center, Randomized, Double-Blind, Placebo Controlled, Crossover Study to Assess the Effect of Aleglitazar on the Pharmacokinetics and Pharmacodynamics of Ethinyl Estradiol and Levonorgestrel as Components of the Oral Contraceptive Microgynon® [NCT01615354]	Phase 1	18 participants (Actual)	Interventional	2012-07-31	Completed
Cervical Preparation of Abortions Under Paracervical Block in the First Trimester: A Randomized Clinical Trial [NCT03043014]		110 participants (Actual)	Interventional	2017-06-01	Completed
Mifepristone Induction for Fetal Demise, a Randomized Control Trial [NCT02620904]	Phase 4	9 participants (Actual)	Interventional	2016-07-14	Terminated(stopped due to unable to recruit. Projected completion was 2018 however, enrollment and recruitment were difficult. The study was terminated due to inability to enroll.)
An Open-Label, Randomized, Two-Way Crossover Study to Investigate the Potential Pharmacokinetic Interaction of Padsevonil With Oral Contraceptives in Healthy Female Participants [NCT04131517]	Phase 1	14 participants (Actual)	Interventional	2019-10-23	Terminated(stopped due to Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures)
A Randomized Trial of Mifepristone Antagonization With High-Dose Progesterone to Prevent Medical Abortion [NCT03774745]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2019-02-11	Terminated(stopped due to Safety)
A Randomized, Placebo-Controlled, Double-Blinded Study of Mifepristone in Midtrimester Termination of Pregnancy [NCT00382538]		64 participants	Interventional	2005-03-31	Completed
Acceptability and Feasibility of Medical Abortion in Mexico, Puerto Rico, Armenia and Azerbaijan: A Study of Buccal Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days' Gestation [NCT00386282]		1,250 participants (Actual)	Interventional	2006-09-30	Completed
Glucocorticoid Receptor Blockade With Mifepristone in Patients With Mild Adrenal Hypercortisolism [NCT01990560]	Phase 4	8 participants (Actual)	Interventional	2013-11-30	Completed
Prospective Non Interventional Phase IV Multi-centre Canadian Study on the Effectiveness and Safety of Combination Mifepristone/Misoprostol for Medical Abortion Under 63 Days Gestation [NCT04905251]		3,000 participants (Anticipated)	Observational	2022-02-22	Recruiting
The HYsteroscopic Miscarriage MaNagement (HYMMN) Trial [NCT04751500]		149 participants (Actual)	Interventional	2021-01-31	Completed
A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Female Patients With Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) [NCT03675581]	Phase 1	17 participants (Actual)	Interventional	2018-11-08	Completed
Efficacy of Mifepristone (RU-486) in the Treatment of Bipolar Depression. [NCT00359125]	Phase 2	0 participants (Actual)	Interventional	2006-07-31	Withdrawn
A Phase I Trial to Investigate the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung Cancer [NCT02751385]	Phase 1	2 participants (Actual)	Interventional	2016-05-20	Terminated(stopped due to Terminated- Study halted due to low recruitment.)
Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial [NCT05322252]	Phase 4	30 participants (Anticipated)	Interventional	2022-07-01	Recruiting
A Randomized, Placebo-controlled, Dose Escalating, Phase II Trial of the Anti -HIV-Activity and Safety of VGX-410 (Mifepristone) in HIV-1 Infected Subjects [NCT00352911]	Phase 2	19 participants (Actual)	Interventional	2006-07-31	Completed
Cervical Preparation for Surgical Abortion at 12-14 Weeks: a Prospective, Randomized, Evaluator-blinded, Multicenter, Controlled Comparison Between Mifepristone, Misoprostol and Their Combination [NCT01795599]	Phase 3	198 participants (Anticipated)	Interventional	2013-05-31	Recruiting
Acceptability and Feasibility of Medical Abortion in Singapore: A Study of 800 μg Buccal Misoprostol Following 200 mg Mifepristone for Abortion Through 70 Days Gestation [NCT02985229]	Phase 3	130 participants (Actual)	Interventional	2016-10-31	Completed
Mifepristone and Misoprostol for 2nd Trimester Termination of Pregnancy (13-22 Weeks LMP) in Burkina Faso [NCT03269279]	Phase 3	100 participants (Anticipated)	Interventional	2017-05-20	Recruiting
A Study to Investigate the Pharmacokinetic Drug-drug Interaction Following Oral Administration of Ethinylestradiol/Levonorgestrel (Microgynon®) and BI 409306 in Healthy Korean Premenopausal Female Subjects (an Open-label, Two-period, Fixed-sequence Study) [NCT03193307]	Phase 1	16 participants (Actual)	Interventional	2017-06-29	Completed
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients With Metastatic Castration Resistant Prostate Cancer (CRPC) [NCT02012296]	Phase 1/Phase 2	88 participants (Actual)	Interventional	2013-12-13	Completed
A Multicenter，Prospective Clinical Trial for Reducing Remaining Submucous Fibroids Volume and Preventing Recurrence by Treating With GnRH Analogues or Mifepristone After Transcervical Resection of Type I-II Myoma [NCT05898321]		294 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
Mifepristone Dynamic Testing for Diagnosis for Central Adrenal Insufficiency [NCT04588688]	Phase 2	3 participants (Actual)	Interventional	2021-05-05	Terminated(stopped due to low recruitment)
"A Study of Acceptability and Feasibility of an Outpatient Day Procedure for Medical Abortion at 13-18 Weeks Gestation in Two Public Sector Hospitals in Nepal" [NCT05046041]	Phase 4	120 participants (Actual)	Interventional	2020-11-25	Completed
Introducing Mifepristone-Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh [NCT01798017]	Phase 4	1,738 participants (Actual)	Interventional	2012-11-30	Completed
Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals [NCT01419535]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2011-11-29	Completed
Mifepristone in Refractory Depression [NCT00186056]		31 participants (Actual)	Interventional	2003-01-31	Completed
A Randomized Comparison of Same-Day Oral Mifepristone-Misoprostol to Misoprostol Only for Cervical Preparation in Second Trimester Surgical Abortion [NCT02412618]	Phase 4	100 participants (Actual)	Interventional	2012-09-30	Completed
Medication Development in Alcoholism: Investigating Glucocorticoid Antagonists [NCT01548417]	Phase 2	56 participants (Actual)	Interventional	2012-03-31	Completed
An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease [NCT01925092]	Phase 3	0 participants (Actual)	Interventional	2013-08-31	Withdrawn(stopped due to Lack of enrollment)
Alternative Provision of Medication Abortion Via Advance Provision [NCT03829696]	Phase 4	0 participants (Actual)	Interventional	2020-01-31	Withdrawn(stopped due to The study is not proceeding at this time.)
Mifepristone as an Adjunct to Transcervical Balloon for Labor Induction (MiLI): A Randomized Clinical Trial [NCT05097326]	Phase 3	30 participants (Actual)	Interventional	2022-06-27	Completed
Developing Memory Reconsolidation Blockers as Novel PTSD Treatments [NCT01490697]	Phase 4	34 participants (Actual)	Interventional	2009-03-31	Completed
Novel Therapeutics in PTSD: A Randomized Clinical Trial of Mifepristone [NCT01739335]	Phase 2	81 participants (Actual)	Interventional	2012-11-19	Completed
Mifepristone and Misoprostol Compared With Misoprostol Alone for Second Trimester Abortion [NCT03044093]	Phase 4	200 participants (Anticipated)	Interventional	2017-01-31	Recruiting
Why Antiprogestrone (Mifepristone) and Cyp 26 Inhibitor Must be Combined With Tamoxifen or ( Tamoxifen and Retinoic Acid) for Treating Early Breast Cancer [NCT05016349]	Phase 3	160 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
The Effects of Multiple Doses of Baricitinib on the Pharmacokinetics of a Single Dose of an Oral Contraceptive in Healthy Female Subjects [NCT01896726]	Phase 1	20 participants (Actual)	Interventional	2013-07-31	Completed
Evaluation of Cortisol Resistance in Young Sedentary and Endurance-trained Men and Elderly Sedentary Men [NCT01294319]	Phase 2	51 participants (Actual)	Interventional	2011-01-24	Completed
A Single-blind, Placebo-controlled, 2-period, Fixed Sequence Study to Determine the Effects of Coadministration of Fostamatinib 100 mg Twice Daily on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Subjects [NCT01276262]	Phase 1	22 participants (Actual)	Interventional	2011-03-31	Completed
Treatment of Schizoaffective Disorder Using Mifepristone [NCT00725270]	Phase 2/Phase 3	12 participants (Actual)	Interventional	1998-04-30	Terminated(stopped due to Lack of funding.)
Mifepristone Versus Placebo to Treat Adenomyosis: a Double-blind, Multicentre，Randomized Clinical Trial [NCT03520439]	Phase 2/Phase 3	134 participants (Actual)	Interventional	2018-05-19	Completed
Cervical Preparation Before Dilation and Evacuation in the Second Trimester: A Multicenter Randomized Trial Comparing Osmotic Dilators Alone to Dilators Plus Adjunctive Misoprostol or Adjunctive Mifepristone. [NCT01751087]		300 participants (Actual)	Interventional	2013-01-31	Completed
A Phase 1, Open-Label, Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inhibitor (Itraconazole) of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites [NCT03259542]	Phase 1	33 participants (Actual)	Interventional	2017-08-09	Completed
A Phase 1, Open-Label, Fixed-Sequence, Crossover Drug-Drug Interaction Study in Healthy Subjects to Determine the Effects of a Strong Inducer of Cytochrome P450 3A on Exposure to Mifepristone and Its Metabolites [NCT03258372]	Phase 1	48 participants (Actual)	Interventional	2017-08-16	Completed
Targeting Progesterone Signaling for Breast Cancer Prevention in BRCA1 Carriers: a Pilot Study [NCT05062174]		0 participants (Actual)	Observational	2021-11-01	Withdrawn(stopped due to PI decision to cancel research)
A 4-week, Double-blind, Placebo-controlled Study of the Efficacy and Safety of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers [NCT00698022]	Phase 1	76 participants (Actual)	Interventional	2008-11-30	Completed
Protocol Title: Reducing Complications and Patient Barriers in Second Trimester Abortion: Pre-Operative Effects of Mifepristone (POEM) on Dilatation and Evacuation Services [NCT01862991]		80 participants (Actual)	Interventional	2013-07-31	Completed
Tumor Necrosis Factor (TNF) and Glucocorticoid Antagonist for Gulf War Illness (GWI)-Associated Multi-symptom Disease Homeostasis Reset [NCT04254627]	Phase 1	20 participants (Anticipated)	Interventional	2021-09-24	Recruiting
Glucocorticoid Antagonist Treatment for Tobacco Use Disorder [NCT03248713]	Early Phase 1	8 participants (Actual)	Interventional	2017-11-29	Terminated(stopped due to Lack of recruitment)
Mifepristone and Misoprostol Versus Misoprostol Alone for Uterine Evacuation After Early Pregnancy Failure: a Randomized Double Blind Placebo-controlled Comparison (Triple M Trial) [NCT03212352]	Phase 4	342 participants (Actual)	Interventional	2018-06-27	Terminated(stopped due to Advised by DSMB based on interim-analysis, highly significant difference.)
An Open-Label, Randomized Crossover Study to Evaluate the Acceptability and Preference for Contraceptive Options in Healthy HIV-Uninfected Female Adolescents, 16-17 Years of Age, as Proxy for HIV Prevention Methods [NCT02404038]		131 participants (Actual)	Interventional	2015-07-31	Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00133705 (1) [back to overview]	Uterine Volume
NCT00186056 (1) [back to overview]	Hamilton Depression Rating Scale
NCT00255177 (1) [back to overview]	Mean Log Change in Viral Load From Baseline (Day 1) to Day 28
NCT00285818 (1) [back to overview]	Hamilton Depression Rating Scale Score
NCT00352911 (1) [back to overview]	Mean Log Change in Viral Load From Baseline (Day 1) to Day 56
NCT00422201 (2) [back to overview]	Glycemic Disorders Improved or Normalized
NCT00422201 (2) [back to overview]	Features of Cushing's Syndrome
NCT00459290 (8) [back to overview]	Overall Survival
NCT00459290 (8) [back to overview]	Progression-free Survival
NCT00459290 (8) [back to overview]	Progression-free Survival at 6 Months
NCT00459290 (8) [back to overview]	Progression-free Survival by Age (y)
NCT00459290 (8) [back to overview]	Progression-free Survival by Performance Status
NCT00459290 (8) [back to overview]	Progression-free Survival by Platinum Sensitivity
NCT00459290 (8) [back to overview]	Proportion of Patients With Objective Tumor Response
NCT00459290 (8) [back to overview]	Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
NCT00468299 (2) [back to overview]	Complete Abortion at One Week
NCT00468299 (2) [back to overview]	Number of Women With Complete Abortion 24-48hrs After Receiving Medical Treatment for Early Pregnancy Failure.
NCT00569582 (2) [back to overview]	Decrease in Diastolic Blood Pressure.
NCT00569582 (2) [back to overview]	Improvement in Diabetes and/or Glucose Intolerance.
NCT00637494 (2) [back to overview]	Proportion of Mifepristone Treated Patients With Plasma Drug Concentrations Equal to or Above 1637 ng/mL vs. Placebo Treated Patients Who Achieve a ≤ 50% Reduction in BPRS-PSS at Days 7 and 56
NCT00637494 (2) [back to overview]	Proportion of Mifepristone vs. Placebo Treated Patients With at Least a 50% Reduction From Baseline in Brief Psychiatric Rating Scale-Positive Symptom Subscale (BPRS-PSS) at Days 7 and 56
NCT00698022 (4) [back to overview]	Percentage of Participants With <5% and <7% Increase From Baseline in Body Weight
NCT00698022 (4) [back to overview]	Percentage of Participants With One or More Adverse Events
NCT00698022 (4) [back to overview]	Percentage of Participants Discontinued From the Study Due to an Adverse Event
NCT00698022 (4) [back to overview]	Change From Baseline in Body Weight
NCT00725270 (2) [back to overview]	Change in Mood Symptoms
NCT00725270 (2) [back to overview]	Change in Positive Psychotic Symptoms Over the Course of Treatment
NCT00764881 (110) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA)
NCT00764881 (110) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1
NCT00764881 (110) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3
NCT00764881 (110) [back to overview]	Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6
NCT00764881 (110) [back to overview]	Percentage of Participants With at Least 1 Intracyclic Bleeding Episode
NCT00764881 (110) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1
NCT00764881 (110) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3
NCT00764881 (110) [back to overview]	Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by Vaginal pH at Cycle 6
NCT00764881 (110) [back to overview]	Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)
NCT00764881 (110) [back to overview]	Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS)
NCT00764881 (110) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Difference in Duration Between Longest and Shortest Spotting-only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Length of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Number of Spotting Only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Maximum Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Maximum Length of Intracyclic Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Maximum Length of Spotting-only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Female Sexual Distress Scale (FSDS-R) Total Score
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Arousal)
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Desire)
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Lubrication)
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Orgasm)
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Pain)
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Domain Score (Satisfaction)
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in FSFI Total Score
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Anxiety
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Depressed Mood
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - General Health
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Positive Well-being
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Self-control
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) - Vitality
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Psychological General Well-Being Index (PGWBI) Global Score
NCT00764881 (110) [back to overview]	Mean Change From Baseline to Cycle 6 in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score
NCT00764881 (110) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Mean Length of Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Mean Length of Spotting-only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Number of Bleeding / Spotting Days in Reference Period 1
NCT00764881 (110) [back to overview]	Number of Bleeding / Spotting Days in Reference Period 2
NCT00764881 (110) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 1
NCT00764881 (110) [back to overview]	Number of Bleeding / Spotting Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 1
NCT00764881 (110) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 3
NCT00764881 (110) [back to overview]	Number of Intracyclic Bleeding Days at Cycle 6
NCT00764881 (110) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Number of Intracyclic Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Number of Spotting Only Days in Reference Period 1
NCT00764881 (110) [back to overview]	Number of Spotting Only Days in Reference Period 2
NCT00764881 (110) [back to overview]	Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Atrophy Symptom Questionnaire (ASQ)
NCT00764881 (110) [back to overview]	Number of Spotting Only Episodes in Reference Period 2
NCT00764881 (110) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 1
NCT00764881 (110) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 3
NCT00764881 (110) [back to overview]	Onset of Withdrawal Bleeding Episodes at Cycle 6
NCT00764881 (110) [back to overview]	Percentage of Participants With Improvement in Participant's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00764881 (110) [back to overview]	Percentage of Participants With Improvement in the Investigator's Assessment in Clinical Global Impression (CGI) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Female Sexual Distress Scale (FSDS-R) Total Score at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Arousal) at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Arousal) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Desire) at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Desire) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Lubrication) at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Lubrication) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Orgasm) at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Orgasm) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Pain) at Baseline.
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Pain) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Domain Score (Satisfaction) at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Total Score at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of FSFI Total Score at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Baseline
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Short Version) Total Score at Cycle 6
NCT00764881 (110) [back to overview]	The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Baseline
NCT00832871 (3) [back to overview]	Toxicity Associated With Adrenal Insufficiency
NCT00832871 (3) [back to overview]	Overall Survival
NCT00832871 (3) [back to overview]	Duration of Response
NCT00867360 (3) [back to overview]	Change in Psychotic Symptoms Subscale (PSS) of the Brief Psychiatric Rating Scale (BPRS)
NCT00867360 (3) [back to overview]	Change in Mean Cortisol Level
NCT00867360 (3) [back to overview]	% Change in Mean Evening Pre- and Post- Florinef Cortisol After Treatment With Either Mifepristone or Placebo
NCT00936741 (2) [back to overview]	Number of Participants With Adverse Events
NCT00936741 (2) [back to overview]	The Long-term Benefit of Mifepristone Treatment in Cushing's Syndrome as Measured by Changes in the Score on the Physician's Global Assessment of Disease Severity
NCT00986921 (3) [back to overview]	Time for Completion of Procedure
NCT00986921 (3) [back to overview]	Moderate or Severe Pain Overnight
NCT00986921 (3) [back to overview]	Assessment of Ease of Procedure by Operator
NCT01134198 (1) [back to overview]	Number of Participants With Relapse by Days 10 and 28
NCT01212588 (15) [back to overview]	Symptom Change - SCL-90-R
NCT01212588 (15) [back to overview]	Symptom Change - BPDSI Subscales
NCT01212588 (15) [back to overview]	Symptom Change - BPDSI Subscales
NCT01212588 (15) [back to overview]	Symptom Change - SCL-90-R
NCT01212588 (15) [back to overview]	Symptom Change - BPDSI Subscales
NCT01212588 (15) [back to overview]	Symptom Change - SCL-90-R
NCT01212588 (15) [back to overview]	Symptom Change - CGI-I
NCT01212588 (15) [back to overview]	Symptom Change - CGI-S
NCT01212588 (15) [back to overview]	Symptom Change - BPRS
NCT01212588 (15) [back to overview]	Durable Symptom Change
NCT01212588 (15) [back to overview]	Levels of Cortisol
NCT01212588 (15) [back to overview]	Metacognitive Capacity
NCT01212588 (15) [back to overview]	Number of Participants With Possibly and Probably Related Adverse Events
NCT01212588 (15) [back to overview]	Rapid Symptom Change
NCT01212588 (15) [back to overview]	Symptom Change - Borderline Checklist
NCT01294319 (2) [back to overview]	Proportion of Suppressors After Dexamethasone
NCT01294319 (2) [back to overview]	Post-dexamethasone Cortisol Level
NCT01328184 (18) [back to overview]	Number of Participants With Clinically Relevant Abnormalities in Physical Examination, Vital Signs, ECG and Clinical Laboratory Tests.
NCT01328184 (18) [back to overview]	Levonorgestrel: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]	Assessment of Tolerability
NCT01328184 (18) [back to overview]	Ethinylestradiol: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Mean Residence Time at Steady State (MRTpo,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Terminal Half-life at Steady State (t1/2,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Terminal Rate Constant at Steady State (λz,ss)
NCT01328184 (18) [back to overview]	Ethinylestradiol: Time From Last Dosing to Maximum Measured Concentration (Tmax,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Apparent Clearance at Steady State (CL/Fss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Apparent Volume of Distribution During the Terminal Phase at Steady State (Vz/Fss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Area Under the Curve at Steady State Over the Uniform Dosing Interval τ (AUCτ,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Maximum Measured Concentration (Cmax,ss)
NCT01328184 (18) [back to overview]	Levonorgestrel: Mean Residence Time at Steady State (MRTpo,ss)
NCT01333098 (4) [back to overview]	Cognitive Changes Over Time, as Measured by Between Group and Within-subjects Comparison of Neuropsychological Measures.
NCT01333098 (4) [back to overview]	Number of Participants With Self-reported Side Effects
NCT01333098 (4) [back to overview]	Drug Acceptability, as Measured by Number of Participants With Dose-limiting Side Effects
NCT01333098 (4) [back to overview]	Anxiety Symptoms
NCT01371565 (1) [back to overview]	Number of Participants With Adverse Events
NCT01419535 (6) [back to overview]	Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
NCT01419535 (6) [back to overview]	Change in Insulin Sensitivity Index
NCT01419535 (6) [back to overview]	Change in Fasting Plasma Glucose
NCT01419535 (6) [back to overview]	Change in Fasting Insulin Levels
NCT01419535 (6) [back to overview]	Adipose-tissue Insulin Sensitivity Index (Adipo-SI)
NCT01419535 (6) [back to overview]	Adipose-tissue Insulin Resistance Index (Adipo-IR)
NCT01436279 (8) [back to overview]	Acceptability to Patient
NCT01436279 (8) [back to overview]	Cervical Dilation Achieved
NCT01436279 (8) [back to overview]	Operative Time
NCT01436279 (8) [back to overview]	Difficulty of Procedure
NCT01436279 (8) [back to overview]	Pain Medication (Fentanyl) During the Abortion
NCT01436279 (8) [back to overview]	Pain Medication (Midazolam) During the Abortion
NCT01436279 (8) [back to overview]	Subject Discomfort Before the Abortion
NCT01436279 (8) [back to overview]	Length of Procedure
NCT01490697 (2) [back to overview]	Change From Baseline in the Impact of Event Scale-Revised (IES-R) Total Score
NCT01490697 (2) [back to overview]	Physiological Posttraumatic Stress Disorder (PTSD) Probability as Determined From Psychophysiologic Responses to Traumatic Recollection
NCT01548417 (2) [back to overview]	Drinking
NCT01548417 (2) [back to overview]	Craving to Drink
NCT01615731 (8) [back to overview]	Total Procedure Time
NCT01615731 (8) [back to overview]	Adverse Events
NCT01615731 (8) [back to overview]	Maximum Cervical Dilation
NCT01615731 (8) [back to overview]	Pain Perceived by Patient
NCT01615731 (8) [back to overview]	Procedure Time
NCT01615731 (8) [back to overview]	Adverse Events (EBL)
NCT01615731 (8) [back to overview]	Ease of Procedure by Blinded Surgeon
NCT01615731 (8) [back to overview]	Overall Patient Experience
NCT01631682 (1) [back to overview]	Change From Baseline Skin Conductance Response
NCT01636063 (1) [back to overview]	Initial Cervical Dilation at the Time of Surgical Abortion
NCT01739335 (12) [back to overview]	Change in CAPS Total Score From Baseline to 4-week and 12-week
NCT01739335 (12) [back to overview]	Change in Sleep Quality (Measured by the PSQI Total Score) From Baseline to 4-Week and 12-Week
NCT01739335 (12) [back to overview]	Changes in PTSD Symptom Severity (Measured by the Stressful Life Total Score From the PTSD Checklist) From Baseline to 4-Week and 12-Week
NCT01739335 (12) [back to overview]	Change in Anger Level (Measured by the STAXI Total Score) From Baseline to 4-Week and 12-Week
NCT01739335 (12) [back to overview]	Change in Depression (Measured by the BDI Total Score) From Baseline to 4-Week and 12-Week
NCT01739335 (12) [back to overview]	Change in Adrenocorticotropic Hormone (ACTH) From Baseline to 1-week
NCT01739335 (12) [back to overview]	Change in Adrenocorticotropic Hormone (ACTH) From Baseline to 4-week
NCT01739335 (12) [back to overview]	Change in Plasma Cortisol From Baseline to 1-Week
NCT01739335 (12) [back to overview]	Change in Plasma Cortisol From Baseline to 4-Week
NCT01739335 (12) [back to overview]	Change in CAPS Avoidance Symptom Scores From Baseline to 4-Week and 12-Week
NCT01739335 (12) [back to overview]	Change in CAPS Hyperarousal Symptom Scores From Baseline to 4-Week and 12-Week
NCT01739335 (12) [back to overview]	Change in CAPS Intrusive Symptom Scores From Baseline to 4-Week and 12-Week
NCT01751087 (9) [back to overview]	Complications From Procedure
NCT01751087 (9) [back to overview]	Chills (Any) After Day 2 Medication Administration
NCT01751087 (9) [back to overview]	Ability to Complete the D&E on the First Attempt
NCT01751087 (9) [back to overview]	Initial Cervical Dilation
NCT01751087 (9) [back to overview]	Patient Satisfaction With Cervical Prep
NCT01751087 (9) [back to overview]	Operative Time
NCT01751087 (9) [back to overview]	Need for Mechanical Dilation
NCT01751087 (9) [back to overview]	Ease of Mechanical Dilation
NCT01751087 (9) [back to overview]	Physician Satisfaction With Cervical Preparation
NCT01862991 (2) [back to overview]	Adverse Events
NCT01862991 (2) [back to overview]	Procedure Time
NCT01896726 (4) [back to overview]	PK: Cmax of Levonorgestrel
NCT01896726 (4) [back to overview]	PK: AUC(0-∞) of Levonorgestrel
NCT01896726 (4) [back to overview]	PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)] of Ethinyl Estradiol
NCT01896726 (4) [back to overview]	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ethinyl Estradiol
NCT01990560 (11) [back to overview]	Waist Circumference
NCT01990560 (11) [back to overview]	State Trait Anxiety Inventory (STAI)
NCT01990560 (11) [back to overview]	Quality of Life
NCT01990560 (11) [back to overview]	Hospital Anxiety and Depression Scale (HADS)
NCT01990560 (11) [back to overview]	HOMA-IR
NCT01990560 (11) [back to overview]	Fasting Lipid Profile
NCT01990560 (11) [back to overview]	CushingQoL
NCT01990560 (11) [back to overview]	Nottingham Health Profile (NHP)
NCT01990560 (11) [back to overview]	Body Mass Index (BMI)
NCT01990560 (11) [back to overview]	Weight
NCT01990560 (11) [back to overview]	A1C Level
NCT02012296 (7) [back to overview]	Cortisol
NCT02012296 (7) [back to overview]	Radiographic PFS
NCT02012296 (7) [back to overview]	Thyroid Stimulating Hormone
NCT02012296 (7) [back to overview]	Testosterone
NCT02012296 (7) [back to overview]	PSA Progression-free Survival
NCT02012296 (7) [back to overview]	Number of Participants With Positive GR Expression Within Circulating Tumor Cells (CTCs)
NCT02012296 (7) [back to overview]	Number of Participants With Positive AR Expression Within Circulating Tumor Cells (CTCs)
NCT02012491 (6) [back to overview]	Uterine Asperation
NCT02012491 (6) [back to overview]	Frequency of Serious Adverse Events Between Study Arms.
NCT02012491 (6) [back to overview]	Gestational Sac Expulsion by the 30-day Telephone Call
NCT02012491 (6) [back to overview]	Gestational Sac Expulsion by the Second Follow-up Visit at Day 8
NCT02012491 (6) [back to overview]	Gestational Sac Expulsion With One Treatment Dose on Day 3 (Visit 2) and no Need for Additional Medical or Surgical Intervention Within 30 Days of Treatment.
NCT02012491 (6) [back to overview]	Adverse Event Reported by Participants
NCT02179749 (2) [back to overview]	Drinking Quantity Per Day
NCT02179749 (2) [back to overview]	Craving
NCT02243709 (3) [back to overview]	Number of Participants Experiencing Adverse Events in the Mifepristone Versus Placebo Group as a Measure of Safety and Tolerability
NCT02243709 (3) [back to overview]	Alcohol Craving Score on the Alcohol Craving Questionnaire in the Mifepristone Versus Placebo Group
NCT02243709 (3) [back to overview]	Drinking Consumption in the Mifepristone Verses Placebo Group
NCT02412618 (2) [back to overview]	Initial Cervical Dilation
NCT02412618 (2) [back to overview]	Patient Acceptability and Assessment of Pain and Side Effects (5-point Likert Scale)
NCT02620904 (1) [back to overview]	Time to Delivery of Fetus
NCT02689804 (10) [back to overview]	Area Under the Curve From Time 0 to 24 Hours of Serum LNG Concentration
NCT02689804 (10) [back to overview]	Area Under the Curve From Time 0 to 24 Hours of Serum UPA Concentration
NCT02689804 (10) [back to overview]	Clearance of Serum LNG
NCT02689804 (10) [back to overview]	Clearance of Serum UPA
NCT02689804 (10) [back to overview]	Elimination Half-life of Serum LNG
NCT02689804 (10) [back to overview]	Elimination Half-life of Serum UPA
NCT02689804 (10) [back to overview]	Maximum Concentration of Serum LNG
NCT02689804 (10) [back to overview]	Maximum Concentration of Serum UPA
NCT02689804 (10) [back to overview]	Time to Maximum Concentration of Serum LNG
NCT02689804 (10) [back to overview]	Time to Maximum Concentration of Serum UPA
NCT02751385 (3) [back to overview]	Maximum Measured Concentration (Cmax) of Ethinylestradiol and Levonorgestrel
NCT02751385 (3) [back to overview]	Area Under the Concentration-time Curve of the the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT02751385 (3) [back to overview]	Area Under the Concentration-time Curve of the Ethinylestradiol and Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity).
NCT03052400 (13) [back to overview]	LDL-cholesterol
NCT03052400 (13) [back to overview]	PSA
NCT03052400 (13) [back to overview]	Hemoglobin A1c
NCT03052400 (13) [back to overview]	Systolic BP
NCT03052400 (13) [back to overview]	Uric Acid
NCT03052400 (13) [back to overview]	Weight
NCT03052400 (13) [back to overview]	Hypoglycemic Events
NCT03052400 (13) [back to overview]	Diastolic BP
NCT03052400 (13) [back to overview]	Cortisol
NCT03052400 (13) [back to overview]	Body Mass Index
NCT03052400 (13) [back to overview]	Basal Insulin Dose
NCT03052400 (13) [back to overview]	Adverse Events
NCT03052400 (13) [back to overview]	ACTH
NCT03320057 (6) [back to overview]	Number of Pharmacists Who Report Being Satisfied With Pharmacy Dispensing of Mifeprex
NCT03320057 (6) [back to overview]	Number of Pharmacists Who Objected to Participate in Dispensing Mifeprex
NCT03320057 (6) [back to overview]	Number of Participants With an Adverse Event
NCT03320057 (6) [back to overview]	Number of Participants With a Complete Abortion With Medication Alone and Who do Not Require a Surgical Procedure to Complete the Abortion
NCT03320057 (6) [back to overview]	Number of Participants Who Report Being Satisfied With Obtaining Mifeprex in the Pharmacy
NCT03320057 (6) [back to overview]	Difference in Pharmacists' Mean Knowledge Score Related to Medication Abortion
NCT03675581 (6) [back to overview]	Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03675581 (6) [back to overview]	Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03675581 (6) [back to overview]	Area Under the Concentration-time Curve of Levonorgestrel in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz)
NCT03675581 (6) [back to overview]	Maximum Measured Concentration of Levonorgestrel in Plasma (Cmax)
NCT03675581 (6) [back to overview]	Maximum Measured Concentration of Ethinylestradiol in Plasma (Cmax)
NCT03675581 (6) [back to overview]	Area Under the Concentration-time Curve of Ethinylestradiol in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
NCT03714880 (7) [back to overview]	Number of Participants That Required Mechanical Dilation
NCT03714880 (7) [back to overview]	Number of Participants That Required Mechanical Dilation
NCT03714880 (7) [back to overview]	Pain Dilator Placement Using Visual Analog Scale
NCT03714880 (7) [back to overview]	Number of Participants That Had Placement of Expected Dilators or More
NCT03714880 (7) [back to overview]	Number of Participants That Experienced Complications
NCT03714880 (7) [back to overview]	Cervical Dilation
NCT03714880 (7) [back to overview]	"Provider Assessment of Procedure as Very Easy or Easy"
NCT03774745 (5) [back to overview]	Expulsion During Follow-up Evaluation
NCT03774745 (5) [back to overview]	Continuing Pregnancy Based on Ultrasound Examination
NCT03774745 (5) [back to overview]	Number of Participants With Change in Serum Progesterone and hCG During Follow-up
NCT03774745 (5) [back to overview]	Number of Participants With Adverse Events During Follow-up Evaluation
NCT03774745 (5) [back to overview]	Medical Safety During Treatment and Follow-up
NCT04131517 (8) [back to overview]	Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Levonorgestrel in Part 1
NCT04131517 (8) [back to overview]	Steady State Plasma Concentration (Cmax,ss) of Padsevonil in Part 1
NCT04131517 (8) [back to overview]	Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) in Part 1
NCT04131517 (8) [back to overview]	Percentage of Participants With Serious TEAEs in Part 1
NCT04131517 (8) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Ethinylestradiol in Part 1
NCT04131517 (8) [back to overview]	Area Under the Concentration-time Curve From Time 0 to Time Tau (AUC[0-tau]) of Padsevonil in Part 1
NCT04131517 (8) [back to overview]	Maximum Observed Plasma Concentration (Cmax) of Levonorgestrel in Part 1
NCT04131517 (8) [back to overview]	Area Under the Concentration-time Curve From Time 0 to Infinity (AUC[0-inf]) of Ethinylestradiol in Part 1
NCT04588688 (4) [back to overview]	Number of Study Participants With Complete Study Data Captured
NCT04588688 (4) [back to overview]	Peak Cortisol Measured After Mifepristone
NCT04588688 (4) [back to overview]	Absolute ACTH After Mifepristone
NCT04588688 (4) [back to overview]	Number of Study Participants Recruited

Uterine Volume

Uterine volume is measured in mLs (NCT00133705)
Timeframe: 6 months

Intervention	mL (Mean)
Treatment Group	719
Placebo Group	449

Intervention	copies/mL on log scale (Log Mean)
Placebo	0.30
VGX-410 150mg Daily	0.00
VGX-410 300mg Daily	0.18
VGX-410 300mg Twice Daily	0.04

Intervention	copies/mL on log scale (Log Mean)
VGX-410 (Mifepristone)	0.18
Placebo for VGX-410 (Mifepristone)	0.42

Intervention	Participants (Count of Participants)
	Anemia	Coagulation	Dermatologic	Gastrointestinal	Hemorrhage
Mifepristone	1	2	1	1	1

Intervention	Participants (Count of Participants)
	<5% increase in body weight	<7% increase in body weight
Mifepristone Plus Risperidone	9	13
Risperidone Plus Mifepristone-matched Placebo	3	10
Risperidone-matched Placebo Plus Mifepristone	8	11

Intervention	kilograms (Mean)
Mifepristone Plus Risperidone	2.32
Risperidone Plus Mifepristone-matched Placebo	4.23
Risperidone-matched Placebo Plus Mifepristone	2.87

Intervention	units on a scale (Mean)
	Baseline PSS Scores	Day 9 PSS scores
Mifepristone	7.57	6.0
Placebo	12.0	11.0

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	3.1
EE/LNG (Microgynon) + Placebo	3.7

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	74.8
EE/LNG (Microgynon) + Placebo	74.1

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	86.20
EE/LNG (Microgynon) + Placebo	85.79

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	87.24
EE/LNG (Microgynon) + Placebo	89.94

Intervention	months (Median)
< 60	1.7
60 <70	4.0
>=70	1.7

Intervention	months (Median)
Not Platinum Sensitive	1.7
Platinum Sensitive	1.9

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	79.12
EE/LNG (Microgynon) + Placebo	81.00

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	80.22
EE/LNG (Microgynon) + Placebo	81.17

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	47.88
EE/LNG (Microgynon) + Placebo	48.46

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	49.41
EE/LNG (Microgynon) + Placebo	49.26

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	66.40
EE/LNG (Microgynon) + Placebo	66.66

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	66.95
EE/LNG (Microgynon) + Placebo	67.18

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	60.27
EE/LNG (Microgynon) + Placebo	60.93

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	61.83
EE/LNG (Microgynon) + Placebo	63.58

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	67.75
EE/LNG (Microgynon) + Placebo	67.98

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	69.20
EE/LNG (Microgynon) + Placebo	69.86

contraceptives, postcoital

Description

Cross-References

Synonyms (4)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Research

Studies (1,792)

Study Types

Clinical Trials (203)

Trial Overview

Trial Outcomes

Uterine Volume

Hamilton Depression Rating Scale

Mean Log Change in Viral Load From Baseline (Day 1) to Day 28

Hamilton Depression Rating Scale Score

Mean Log Change in Viral Load From Baseline (Day 1) to Day 56

Glycemic Disorders Improved or Normalized

Features of Cushing's Syndrome

Overall Survival

Progression-free Survival

Progression-free Survival at 6 Months

Progression-free Survival by Age (y)

Progression-free Survival by Performance Status

Progression-free Survival by Platinum Sensitivity

Proportion of Patients With Objective Tumor Response

Number of Participants With Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

Complete Abortion at One Week

Number of Women With Complete Abortion 24-48hrs After Receiving Medical Treatment for Early Pregnancy Failure.

Decrease in Diastolic Blood Pressure.

Improvement in Diabetes and/or Glucose Intolerance.

Proportion of Mifepristone Treated Patients With Plasma Drug Concentrations Equal to or Above 1637 ng/mL vs. Placebo Treated Patients Who Achieve a ≤ 50% Reduction in BPRS-PSS at Days 7 and 56

Proportion of Mifepristone vs. Placebo Treated Patients With at Least a 50% Reduction From Baseline in Brief Psychiatric Rating Scale-Positive Symptom Subscale (BPRS-PSS) at Days 7 and 56

Percentage of Participants With <5% and <7% Increase From Baseline in Body Weight

Percentage of Participants With One or More Adverse Events

Percentage of Participants Discontinued From the Study Due to an Adverse Event

Change From Baseline in Body Weight

Change in Mood Symptoms

Change in Positive Psychotic Symptoms Over the Course of Treatment

Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Anxiety at Cycle 6

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Baseline

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Depressed Mood at Cycle 6

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Baseline

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - General Health at Cycle 6

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Baseline

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Positive Well-being at Cycle 6

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Baseline

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Self-control at Cycle 6

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Baseline

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) - Vitality at Cycle 6

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Baseline

The Mean Absolute Values of Psychological General Well-Being Index (PGWBI) Global Score at Cycle 6

Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Baseline

Vaginal Effects Evaluated by the Mean Absolute Values of Atrophy Symptom Questionnaire (ASQ) at Cycle 6

Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Baseline

Vaginal Effects Evaluated by the Mean Absolute Values of Vaginal Health Assessment (VHA) at Cycle 6

Vaginal Effects Evaluated by the Mean Change From Baseline to Cycle 6 in Vaginal Health Assessment (VHA)

Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 1

Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 3

Percentage of Participants by Maximum Intensity of Intracyclic Bleeding Episodes at Cycle 6

Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 1

Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 3

Percentage of Participants by Maximum Intensity of Withdrawal Bleeding Episodes at Cycle 6

Percentage of Participants With / Without Withdrawal Bleeding at Cycle 1

Percentage of Participants With / Without Withdrawal Bleeding at Cycle 3

Percentage of Participants With / Without Withdrawal Bleeding at Cycle 6

Percentage of Participants With at Least 1 Intracyclic Bleeding Episode

Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 1

Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 3

Percentage of Participants With Presence or Absence of Intracyclic Bleeding at Cycle 6

Vaginal Effects Evaluated by Vaginal pH at Cycle 6

Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Full Analysis Set (FAS)

Change From Baseline to Cycle 6 in the Total of Questions 1 to 6 of the Female Sexual Function Index (FSFI) - Per Protocol Set (PPS)

Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 1

Difference in Duration Between Longest and Shortest Bleeding / Spotting Episodes in Reference Period 2

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	0.54
EE/LNG (Microgynon) + Placebo	0.47

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	0.01
EE/LNG (Microgynon) + Placebo	-0.06

Intervention	Percentage of participants (Number)
	spotting	light	normal	heavy
EE/LNG (Microgynon) + Placebo	80.0	20.0	0.0	0.0
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	75.0	6.3	12.5	6.3

Intervention	Percentage of participants (Number)
	without withdrawal bleeding	with withdrawal bleeding
EE/LNG (Microgynon) + Placebo	2.8	97.2
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	24.8	75.2

Intervention	Percentage of participants (Number)
	no	yes
EE/LNG (Microgynon) + Placebo	87.9	12.1
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	63.1	36.9

Intervention	Percentage of participants (Number)
	with absence of intracyclic bleeding	with presence of intracyclic bleeding
EE/LNG (Microgynon) + Placebo	95.3	4.7
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	84.2	15.8

Intervention	Proportion of participants (Number)
	Vaginal pH < 4.0	Vaginal pH 4.0 - 4.4	Vaginal pH 4.5 - 5.0	Vaginal pH > 5.0
EE/LNG (Microgynon) + Placebo	0.039	0.294	0.637	0.029
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	0.053	0.298	0.521	0.117

Intervention	scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	6.45
EE/LNG (Microgynon) + Placebo	5.98

Intervention	scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	6.43
EE/LNG (Microgynon) + Placebo	6.37

Intervention	Scores on a scale (Mean)
EV/DNG (Natazia, Qlaira, BAY86-5027, SH T00658ID)	-10.0
EE/LNG (Microgynon) + Placebo	-9.6